PKS Advisory Services LLC Makes New $324,000 Investment in Pfizer Inc. (NYSE:PFE)

PKS Advisory Services LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,195 shares of the biopharmaceutical company's stock, valued at approximately $324,000.

Several other institutional investors also recently modified their holdings of the company. PSI Advisors LLC increased its holdings in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after acquiring an additional 391 shares in the last quarter. D Orazio & Associates Inc. boosted its position in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares during the last quarter. Lipe & Dalton grew its holdings in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC increased its position in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 401 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Pfizer Stock Performance

PFE stock traded up $0.11 during midday trading on Friday, hitting $25.12. 17,244,590 shares of the stock traded hands, compared to its average volume of 44,916,586. The stock's fifty day simple moving average is $26.09 and its 200-day simple moving average is $26.97. The firm has a market cap of $142.44 billion, a P/E ratio of 17.81, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.